Lilly to acquire Dermira for $1.1 billion, expanding its portfolio of Phase 3 medicines with the addition of lebrikizumab, an IL-13antibody being studied in Phase 3 for the treatment of moderate-to-severe atopic dermatitis Acquisition also includes QBREXZA, Dermira's medicated cloth for primary axillary hyperhidrosis